Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2022 to 2030

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1 Shift from use of Plasma Derived Proteins to Recombinant Therapies
4.3.1.2 Rising Awareness about Rare Disease Management
4.3.1.3 Increasing Focus on Investments in Rare Disease
4.3.2. Restraints
4.3.2.1 High Cost of Treatment
4.3.2.2 Availability of Alternative Therapies
4.3.3. Opportunities
4.3.3.1 Growth Opportunities in Developing Markets
4.3.3.2 Strategic Approaches such as Partnership and Distribution Agreements
4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2019–2026

5. Key Insights
5.1. New Product Launch and Regulatory Approvals
5.2. Key Mergers & Acquisitions
5.3. Regulatory Scenario by Region/Country

6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
6.3.1. Recombinant Coagulation Factors
6.3.1.1. Recombinant Coagulation Factor VIII
6.3.1.2. Recombinant Coagulation Factor IX
6.3.1.3. Recombinant Coagulation Factor VIIa
6.3.1.4. Others
6.3.2. Human C1 Esterase Inhibitor
6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class

7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
7.3.1. Chinese Hamster Ovary (CHO) Cell Line
7.3.2. Baby Hamster Kidney (BHK) Cell Line
7.3.3. Human Embryonic Kidney (HEK) Cell Line
7.3.4. Others
7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line

8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
8.3.1. Hemophilia A
8.3.2. Hemophilia B
8.3.3. Von Willebrand Disease
8.3.4. Others
8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication

9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region

10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
10.2.1. Recombinant Coagulation Factors
10.2.1.1. Recombinant Coagulation Factor VIII
10.2.1.2. Recombinant Coagulation Factor IX
10.2.1.3. Recombinant Coagulation Factor VIIa
10.2.1.4. Others
10.2.2. Human C1 Esterase Inhibitor
10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
10.3.1. Chinese Hamster Ovary (CHO) Cell Line
10.3.2. Baby Hamster Kidney (BHK) Cell Line
10.3.3. Human Embryonic Kidney (HEK) Cell Line
10.3.4. Others
10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
10.4.1. Hemophilia A
10.4.2. Hemophilia B
10.4.3. Von Willebrand Disease
10.4.4. Others
10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2019–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Cell Line
10.6.3. By Indication
10.6.4. By Country

11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
11.2.1. Recombinant Coagulation Factors
11.2.1.1. Recombinant Coagulation Factor VIII
11.2.1.2. Recombinant Coagulation Factor IX
11.2.1.3. Recombinant Coagulation Factor VIIa
11.2.1.4. Others
11.2.2. Human C1 Esterase Inhibitor
11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
11.3.1. Chinese Hamster Ovary (CHO) Cell Line
11.3.2. Baby Hamster Kidney (BHK) Cell Line
11.3.3. Human Embryonic Kidney (HEK) Cell Line
11.3.4. Others
11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
11.4.1. Hemophilia A
11.4.2. Hemophilia B
11.4.3. Von Willebrand Disease
11.4.4. Others
11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Cell Line
11.6.3. By Indication
11.6.4. By Country/Sub-region

12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
12.2.1. Recombinant Coagulation Factors
12.2.1.1. Recombinant Coagulation Factor VIII
12.2.1.2. Recombinant Coagulation Factor IX
12.2.1.3. Recombinant Coagulation Factor VIIa
12.2.1.4. Others
12.2.2. Human C1 Esterase Inhibitor
12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
12.3.1. Chinese Hamster Ovary (CHO) Cell Line
12.3.2. Baby Hamster Kidney (BHK) Cell Line
12.3.3. Human Embryonic Kidney (HEK) Cell Line
12.3.4. Others
12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
12.4.1. Hemophilia A
12.4.2. Hemophilia B
12.4.3. Von Willebrand Disease
12.4.4. Others
12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Cell Line
12.6.3. By Indication
12.6.4. By Country/Sub-region

13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
13.2.1. Recombinant Coagulation Factors
13.2.1.1. Recombinant Coagulation Factor VIII
13.2.1.2. Recombinant Coagulation Factor IX
13.2.1.3. Recombinant Coagulation Factor VIIa
13.2.1.4. Others
13.2.2. Human C1 Esterase Inhibitor
13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
13.3.1. Chinese Hamster Ovary (CHO) Cell Line
13.3.2. Baby Hamster Kidney (BHK) Cell Line
13.3.3. Human Embryonic Kidney (HEK) Cell Line
13.3.4. Others
13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
13.4.1. Hemophilia A
13.4.2. Hemophilia B
13.4.3. Von Willebrand Disease
13.4.4. Others
13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Cell Line
13.6.3. By Indication
13.6.4. By Country/Sub-region

14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2019–2026
14.2.1. Recombinant Coagulation Factors
14.2.1.1. Recombinant Coagulation Factor VIII
14.2.1.2. Recombinant Coagulation Factor IX
14.2.1.3. Recombinant Coagulation Factor VIIa
14.2.1.4. Others
14.2.2. Human C1 Esterase Inhibitor
14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2019–2026
14.3.1. Chinese Hamster Ovary (CHO) Cell Line
14.3.2. Baby Hamster Kidney (BHK) Cell Line
14.3.3. Human Embryonic Kidney (HEK) Cell Line
14.3.4. Others
14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2019–2026
14.4.1. Hemophilia A
14.4.2. Hemophilia B
14.4.3. Von Willebrand Disease
14.4.4. Others
14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Cell Line
14.6.3. By Indication
14.6.4. By Country/Sub-region

15. Competitive Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2019)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.1.1. Company Details
15.3.1.2. Products Portfolio
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Shire (Takeda Pharmaceutical Company Limited)
15.3.2.1. Company Details
15.3.2.2. Products Portfolio
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Octapharma
15.3.3.1. Company Details
15.3.3.2. Products Portfolio
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Novo Nordisk A/S
15.3.4.1. Company Details
15.3.4.2. Products Portfolio
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Bayer AG
15.3.5.1. Company Details
15.3.5.2. Products Portfolio
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Pfizer Inc.
15.3.6.1. Company Details
15.3.6.2. Products Portfolio
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)
15.3.7.1. Company Details
15.3.7.2. Products Portfolio
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Aptevo Therapeutics
15.3.8.1. Company Details
15.3.8.2. Products Portfolio
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Pharming Group NV
15.3.9.1. Company Details
15.3.9.2. Products Portfolio
15.3.9.3. Financial Overview
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis